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Abstract 
 
Bacterial keratitis is an infectious disease of the cornea that is characterised by 
inflammation. The common pathogens associated with this disease include 
Staphylococcus aureus, coagulase-negative Staphylococcus, Pseudomonas aeruginosa, 
Streptococcus pneumonia and Serratia species, causing 90% of the bacterial keratitis 
cases. Currently, treatment of bacterial infections and inflammation in the eye has the 
problem of anatomic barriers and the delicate nature of the eye. Local drug applied to the 
eye represents a non-invasive, safe and less painful solution than surgery, laser treatments 
or eye injections.  
Ceftazidime is a third generation cephalosporin antibiotic which is effective mainly 
against pathogens that are usually responsible for ophthalmological infections. 
Ceftazidime offers a good coverage against Pseudomonas aeruginosa as well as 
resistance to several types of beta lactamases. 
The aim of the present work was to prepare a mucoadhesive nanoparticle eye drop 
formulation containing ceftazidime to treat eye infections.  
The first step for the development of the eye drop formulation was to prepare a vehicle 
for nanoparticles. Two different polymers were selected: carboxymethyl cellulose and 
hydroxypropylmethyl cellulose, both in low and high viscosity. The selection was based 
in studies of viscosity, zeta potential and interaction with the nanoparticles. After the tests, 
the work continued with hydroxypropylmethyl cellulose. 
The development of mucoadhesive chitosan-nanoparticles are proposed as effective 
delivery systems for ceftazidime through ocular epithelium, taking advantage of the 
favourable biological properties of hyaluronic acid and chitosan to prolong precorneal 
residence time of the antibiotic, enhancing drug accumulation and permeation. 
Nanoparticles were prepared by ionotropic gelation between sodium tripolyphosphate 
and chitosan with the objective to encapsulate ceftazidime. 
The formulations were characterized in terms of pH, osmolality, viscosity, zeta potential, 
particle size distribution and encapsulation efficiency. In addition, the in vitro release and 
permeation studies were performed and the results suggest a prolonged drug release from 
the nanoparticles. The results of nanoparticles interaction with mucin show their 
mucoadhesivity and ability to interact with the ocular surface increasing the drug 
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residence time in the eye. The prepared nanoparticles were subjected to stability and 
microbiological studies with satisfactory results.  
In conclusion, Chitosan/TPP-Hyaluronic Acid nanoparticles proved to be a promising 
platform for ceftazidime delivery in the eye. 
 
Keywords: eye, ophthalmic drug delivery, chitosan nanoparticles, bacterial keratitis, 
ceftazidime. 
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Resumo 
 
O olho é um órgão do corpo humano com uma estrutura e anatomia complexas por 
apresentar diversas barreiras que impedem que os fármacos possam penetrar para o 
tratamento das diversas afeções oculares. As barreiras estão presentes tanto ao nível do 
segmento anterior como posterior. Geralmente, os fármacos são administrados recorrendo 
à administração tópica e às formas farmacêuticas comuns mas as características únicas 
dos tecidos oculares e os mecanismos de defesa do globo ocular dificultam a 
administração de fármacos a este nível, obtendo-se uma baixa resposta terapêutica. Um 
dos desafios das novas formulações terapêuticas de administração ocular é aumentar a 
biodisponibilidade dos fármacos administrados topicamente assim como a sua eficácia 
terapêutica. A administração tópica ocular é desde sempre um desafio devido à 
dificuldade em manter concentrações adequadas de fármaco no local de aplicação durante 
tempo suficiente de modo a obter um adequado efeito farmacológico, o que requer 
repetidas aplicações do fármaco.  
Estes objetivos podem ser atingidos através do recurso a estratégias que aumentem o 
tempo de residência pré-corneal, a mucoadesividade e a penetração através dos tecidos. 
A queratite bacteriana é uma afeção ocular que afeta milhões de pessoas em todo o mundo 
causando problemas oculares graves podendo mesmo causar cegueira. Esta infeção 
conduz à destruição da córnea e tem como principais agentes patogénicos Staphylococcus 
aureus, Staphylococcus coagulase-negativo, Pseudomonas aeruginosa, Streptococcus 
pneumonia e Serratia.  
O projeto desenvolvido visa utilizar a ceftazidima, antibiótico da classe das 
cefalosporinas de terceira geração, que atua na inibição da síntese da parede bacteriana, 
no combate ao principal agente causador da queratite bacteriana, mas não da forma 
convencional em que são normalmente utilizados.  
Para melhorar o tempo de residência do fármaco, foram desenvolvidas nanopartículas 
poliméricas. Estas nanopartículas foram desenvolvidas por gelificação inotrópica entre 
quitosano e tripolifosfato às quais foi adicionado ácido hialurónico. Os componentes 
foram selecionados com base nas suas características de biodegradabilidade, 
biocompatibilidade e mucoadesão com as glicoproteínas da córnea e conjuntiva. O ácido 
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hialurónico foi selecionado pela sua interação com os recetores CD44 presentes na córnea 
e conjuntiva oculares facilitando a penetração das nanoparticulas a nível ocular.  
Para o desenvolvimento das nanopartículas várias proporções dos três principais 
componentes foram sendo testadas variando a sua quantidade, proporções e pH do meio. 
Estas variações foram necessárias para verificar as condições ideais para que, por um lado 
ocorresse a formação das nanopartículas e por outro que estas se mantivessem estáveis e 
não precipitassem. 
 Para que as nanopartículas possam ser corretamente utilizadas têm que ter um veículo 
que permita a sua administração. O veículo foi desenvolvido utilizando polímeros 
mucoadesivos derivados da celulose, a carboximetilcelulose e hidroxipropilmetilcelulose 
utilizados também como agentes viscosificantes e que foram testados em diferentes 
concentrações. Testes de viscosidade, potencial zeta e compatibilidade com as 
nanopartículas produzidas foram desenvolvidos para chegar ao polímero e concentração 
ideais para funcionar como veículo. 
As formulações foram caracterizadas em termos de pH, osmolalidade, viscosidade, 
potencial zeta, distribuição de tamanho das nanoparticulas e eficiência de encapsulação 
do fármaco.    
Adicionalmente foram realizados estudos in vitro de libertação e cedência que 
demonstram uma libertação continuada do fármaco a partir das nanopartículas 
formuladas. Estudos de viscosidade e potencial zeta foram também desenvolvidos na 
avaliação da interação entre a formulação e a mucina ocular comprovando-se a 
mucoadesividade que permite prolongar o tempo de residência ocular e a libertação do 
fármaco. As nanopartículas desenvolvidas foram sujeitas a estudos microbiológicos 
demonstrando ter atividade contra agentes causadores da queratite bacteriana. Os estudos 
de toxicidade desenvolvidos demonstraram resultados satisfatórios pois indicaram que a 
formulação não teve efeitos citotóxicos nas linhas celulares testadas.  
Em conclusão, as nanopartículas de quitosano/TPP-Ácido Hialurónico são uma 
promissora formulação ocular para a veiculação da ceftazidima, promissora no tratamento 
da queratite bacteriana. 
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1. Introduction 
 
The human eye is a small organ that provides sense of sight, allowing the perception of 
shapes, colours and dimensions around the world. In spite of constant environmental 
changes, the eye has the ability to adapt to new conditions (Kansara et al, 2007). It is 
composed of several different structures and layers, with specific physiological roles. One 
of the most important functions of these structures is to protect the ocular globe against 
external aggression. For this protection, there are tight cellular barriers in the anterior and 
posterior parts of the eye that restrict the uptake of fluids and prevent penetration of 
foreign bodies (Almeida et al, 2014). 
According to the World Health Organization, a wide diversity of eye diseases affects 
millions of people around the world and has devastating effects on individuals, leading to 
visual injury and possible ocular blindness that instigate a decline in quality of life 
(WHO). 
Because of all the ocular barriers the design of targeted ocular drug delivery systems to 
overcome them remains one of the greatest challenges in pharmaceutical sciences. Static 
barriers (different layers of cornea, sclera, and retina including blood aqueous and blood–
retinal barriers), dynamic barriers (choroidal and conjunctival blood flow, lymphatic 
clearance, and tear dilution), and efflux pumps in conjunction pose a significant challenge 
for delivery of a drug alone or in a dosage form, especially to the posterior segment 
(Gaudana et al, 2010). 
Topical instillation is the most preferred non-invasive route of drug administration to treat 
diseases affecting the anterior segment. Conventional dosage forms such as eye drops 
account for 90% of the marketed ophthalmic formulations. The reason may be attributed 
to ease of administration and patient compliance (Bravo-Osuna et al, 2016). Nonetheless, 
the ocular bioavailability is very low with topical drop administration. Numerous 
anatomical and physiological constraints such as lacrimation and blinking tear dynamics, 
drainage by gravity, nasolacrimal drainage (the residence volume of the tear film is 7–10 
μL, while the human cul-de-sac may contain about 30 μL volume). The excess is removed 
through the nasolacrimal drainage system (Patel et al, 2015). Less than 5% of topically 
applied dose reaches to deeper ocular tissues. It is difficult to achieve therapeutic drug 
concentration into posterior segment ocular tissues following topical eye drops instillation 
because of the above mentioned barriers. The drug can be delivered to the posterior 
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segment ocular tissues by different modes of administrations such as intravitreal 
injections, periocular injections, and systemic administration. 
One way to overcome some of the eye’s natural anatomical barriers is to take advantage 
of the ocular surface mucosal layer and use its structure to aid in biopharmaceutical 
adherence and penetration by incorporating mucoadhesive substances into the delivery 
system. These mucoadhesive substances can be integrated into a range of different 
delivery systems and used in conjunction with a variety of biopharmaceuticals to make 
an effective device for ocular pharmaceutical delivery. Among different drug delivery 
systems, nanoparticles are being intensively systems. So, nanoparticles are a system that 
have been designed to overcome the barriers, increasing the drug penetration at the target 
site and prolong the drug levels by few intervals of drug administrations in lower doses 
without any toxicity compared to the conventional eye drops (Sheardown and Lorentz, 
2014). 
1.1-Anatomy of the Eye 
 
A close examination of the physiology and anatomy of the eye (Figure 1) is of great 
importance to understand the challenges associated with ocular drug delivery. 
The eyeball is enveloped by a three layer covering which wraps the internal structures. 
The innermost layer is the retina, middle is the uveal coat, and the outermost layer is the 
sclera. The sclera is composed of tough fibrous tissue, which covers the posterior section 
of the eyeball and continues into the anterior eye to form the clear transparent cornea 
(Sheardown and Lorentz, 2014). 
The structure of the eye can be divided in two segments, namely anterior and posterior 
segments (Kansara et al, 2007). 
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Figure 1.1 - Eye anatomy (Reference:/www.virtualmedicalcentre.com/anatomy/the-eye-
andvision/ 28) 
 
The anterior segment comprises two chambers, i.e the anterior (between the cornea and 
iris) and posterior (between iris and lens). The anterior segment of the eye includes 
structures such as the lens, lachrymal system, iris, aqueous humor, ciliary body, pupil, 
conjunctiva, and the cornea (Sheardown and Lorentz, 2014). 
The conjunctiva is a thin transparent membrane which covers the inside surface of the 
eyelids and extends onto the anterior surface of the eye to cover the sclera, meeting the 
corneal epithelium at the limbus. The conjunctiva is vascular and it is composed of three 
layers: epithelium, substantia propria, and the submucosa and it is divided into two main 
regions: the palpebral and bulbar conjunctiva (Patel et al, 2015). The surface epithelial 
cells of the conjunctiva are connected by tight junctions and have scattered goblet cells 
that secrete approximately 2-3 μL of mucous per day, which covers the eye surface, and 
has the function of hydration, cleaning and lubrication and serves as a defence against 
pathogens (Almeida et al, 2014). 
The cornea is a major barrier for traditional topical drug delivery in the treatment of 
anterior segment diseases. It is a transparent, avascular and highly innervated tissue, with 
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11.7 mm diameter and a thickness of 0.5-0.7 mm; the cornea is thicker in the centre than 
in the limbus (Mun et al, 2014). 
The five layers of the cornea are the epithelium, Bowman’s layer, stroma, Descemet’s 
membrane, and the endothelium. The epithelium is the anterior-most layer of the cornea 
consisting of 5–6 layers of cells, joined together by the presence of tight junctions and is 
able to regenerate following an injury The Bowman’s layer is a cellular layer of the stroma 
that is not able to regenerate. The stroma is the thickest layer of the cornea composed of 
collagen fibres and 90% water which provide the cornea with its transparent properties. 
The Descemet’s membrane is an elastic membrane which covers the endothelium. 
(Sheardown and Lorentz, 2014). The corneal epithelium layer possesses tight junction 
cells which limits the entry to small hydrophilic drug molecules following topical 
administration. Moreover, hydrophilic structure of stroma offers limited entry of 
lipophilic compounds. Presence of efflux proteins (P-glycoprotein and multidrug 
resistance protein) on the corneal epithelium also restricts the entry of xenobiotics to the 
anterior segment tissues. Pre-corneal drainage, tears washout and limited contact time are 
major challenges to the anterior segment drug delivery following topical administration. 
To be clinically effective topical formulation has to possess a balance between the 
hydrophilicity and lipophilicity with high contact time (Kansara et al, 2007).). 
The iris is the coloured part of the eye which is located between the cornea and the lens 
and controls the size of the pupil. It has two main layers: the connective tissue rich stroma 
and the pigmented epithelium (Stjernschantz and Astin, 1993). 
The crystalline located posterior to the iris, is attached to the ciliary body which contains 
the ciliary muscle that enables it to change its shape to allow for light to be focused on 
the retina (Sheardown and Lorentz, 2014) 
Separates the aqueous and vitreous humor and is composed of three main parts: lens 
fibers, lens epithelium, and the lens capsule (Sheardown and Lorentz, 2014) 
The aqueous humor is composed of a clear jelly-like fluid that fills the anterior segment 
of the eye, controls intraocular pressure, removes waste and provides nutrients to the 
surrounding tissues (Stjernschantz and Astin, 1993). 
The crystalline is responsible for three main functions: secretion, distribution, and 
collection of tears. The lacrimal gland secretes tears due to the basic need to maintain the 
tear film, from reflex tearing due to stimulation such as irritation or temperature, or due 
to emotional tearing. In healthy individuals, basal tear production ranges from 0.5–2.2 
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μL/min, but this can increase to 300 μL/min for reflex tearing (Sheardown and Lorentz, 
2014). 
The posterior segment of the eye includes the retina, choroid, sclera, macula, fovea, optic 
nerve, and the vitreous humor. 
The vitreous humor is a dense gelatinous substance that fills in the space between the 
posterior side of the lens and the retina. The production of vitreous humor is minor than 
the production of aqueous humor, and has a slow turnover. It main function it’s the 
maintenance of the ocular pressure keeping the retina and crystalline located in the right 
places, being responsible for light refraction (Kumar et al, 2011). 
The retina is a thin membrane which is composed of two layers: the outer pigmented 
epithelium and the inner neuro-epithelium. Overall, the retina is responsible for detecting 
light focused on the retina and converting it to nerve impulses which are sent through the 
optic nerve and into the brain. The retina is dense with photosensitive cells called cones 
and rods (Kumar et al, 2011). 
In the intact retina occurs the absorption of drugs to the blood vessels or its transportation 
by the pigmented epithelium. In the case that the drugs are transported by the pigmented 
epithelium it can be absorbed by the vessels of the choroid (Kumar et al, 2011). 
The choroid located posterior to the retina and the uvea and is responsible for delivering 
oxygen and nourishment to the retina. It is composed of four layers, is heavily 
vascularized, pigmented, and contains connective tissue (Sheardown and Lorentz, 2014). 
The sclera’s function is mainly protective and covers the bulk of the posterior part of the 
eyeball in a thick dense fibrous tissue and muco-polysaccharides. Not only does this 
protect the internal sensitive structures but it also provides a site for attachment for the 
ocular muscles and maintains the shape of the eyeball (Sheardown and Lorentz, 2014). 
The optic nerve is the second cranial nerve and is responsible for vision. Each nerve 
contains approximately one million fibres transmitting information from the rod and cone 
cells of the retina (Kumar et al, 2011). 
 
1.2- Structure of the Tear Film 
 
The tear film is a complex multilayered film that covers the anterior surface of the 
conjunctiva and cornea. It is thought to provide several unique roles and therefore its 
composition needs to be tightly regulated. Its thickness is approximates to be 3 μm. 
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(Sheardown and Lorentz, 2014). It is composed by three layers with different origins and 
composition (lipid, aqueous, and mucous layers) (Figure 2). The lipid layer is produced 
by the meibominan glands and it’s composed by sterols, fatty acids, glycerides and esters, 
polar lipids, the aqueous layer becomes from the lacrimal glands and the main 
composition are proteins, lactoferrin, salts, glucose, urea and water. The mucin layer has 
origin in the conjunctival goblet cells, glands of Moll and Krasse. 
 
 
 
 
Figure 1.2 - Tear film composition (Reference: Morrison and Khutoryanskiy, 2014) 
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Table 1.1 - Tear film layers and functions (Morrison and Khutoryanskiy, 2014) 
Tear film 
layer 
Function 
Lipid layer To prevent evaporation and to provide a barrier  
To provide a smooth optical surface for the refraction light 
To act as a lubricant to aid the eyelid movement  
To form a barrier against tear film 
contamination  
To provide a surfactant layer between the non-polar lipid layer and 
the aqueous layer 
Aqueous layer To prevent tear overflow  
To create a favorable environment for the corneal epithelial cells, 
carry oxygen and nutrients to and from the cornea, and 
allow cell movement over the ocular surface  
To wash away toxic substances and debris during blinking  
To aid in antimicrobial activity through the tear film proteins 
(lipocalin, lactoferrin, lysozyme, and IgA) 
Growth factors present in this tear film phase play a significant role 
in corneal physiology 
Mucous Layer To act as a pathogen barrier using the ocular surface glycocalyx  
Mucin is a lubricant, which allows the eyelid and conjunctiva to move 
smoothly over each another during blinking and ocular movements 
Mucus threads protect the conjunctiva and cornea from injury by 
coating foreign bodies with a slippery mucus  
Mucus aids in glycocalyx formation and wetting the ocular surface 
Mucus helps overcome the hydrophobicity of the corneal surface 
 
1.3- Ocular mucin 
 
Since the concept of mucosal drug delivery involves an intimate relationship between the 
mucin and the delivery system, it is important to understand the composition of the 
mucous layer. Mucins are large glycoproteins which are mainly composed of a protein 
core, carbohydrates and are well glycosylated. There are two main types of mucin: 
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secreted mucins and membrane-associated mucins. Secreted mucins can be further 
divided into soluble and gel-forming mucins. 
Ocular membrane-associated mucins, such as MUC1 and MUC16, are structured to have 
short cytoplasmic tails, a heavily glycosylated extracellular domain which can reach the 
glycocalyx, and a hydrophobic domain which spans the membrane and anchors the 
mucin. These membrane-associated mucins help create a hydrophilic barrier and may 
have their own signalling abilities. Ocular secreted gel-forming mucins, such as MUC 2, 
5AC, and 5B, are the largest glycoproteins, contribute to the viscoelastic properties of 
mucus, and help trap particles and bacteria. Ocular secreted soluble mucins, such as MUC 
7, are the smallest mucins found in the tear film (Sheardown and Lorentz, 2014). 
Approximately 2.5 μL of mucus is produced every day, and it is thought that the mucus 
layer is replenished at least once daily (Gan et al, 2013). 
 
1.4- Routes of drug delivery to the eye  
 
There are different possible routes of drug delivery into the ocular tissues, and the 
selection of the route of administration depends primarily on the target tissue (Urtti, 
2006).  
1.4.1- Topical administration 
It is the most commonly used route of drug administration for the treatment of anterior 
segment complications. However, there are many barriers blocking successful and 
effective topical delivery of biopharmaceuticals to the eye. These challenges include 
ocular anatomical barriers due to the extraordinary and complex structure of the eye, 
biopharmaceutical barriers related to the biopharmaceutical’s properties, and patient 
barriers related to comfort, compliance, and self-administration of the treatment 
(Sheardown and Lorentz, 2014). 
Advantages of this route are relative simplicity of the formulations, minimal storage 
limitations and ease of drug instillation. Disadvantages include limited drug concentration 
for lipophilic agents, pre-corneal losses and the barrier function of the cornea. However, 
regardless of the ease of access to the eye for topical application of medication, efficient 
ocular drug delivery is hampered by a series of clearance mechanisms that protect the 
ocular structures from foreign matter. Upon administration of traditional eye drops they 
are immediately diluted in the tear film, followed by very quick elimination by the action 
of blinking, wash out by tears and nasolacrimal drainage. After instilling eye drops, there 
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remains a very short time where any residual medication is in contact with the cornea, 
during which time there is opportunity for the drug to penetrate into the eye; however, 
due to poor corneal permeability only a very small portion of active pharmaceutical 
ingredient will be capable of crossing the cornea.  Typically, less than 5% of the applied 
drug penetrates the cornea and reaches intraocular tissues (Le Bourlais et al., 1998). 
 
1.4.2- Systemic administration 
For the systemic administration, the blood–aqueous barrier and blood–retinal barrier are 
the major barriers for anterior segment and posterior segment ocular drug delivery, 
respectively. For effective systemic deliver, such as oral or intravenous, a relatively high 
drug concentration needs to be circulating in the blood plasma in order to achieve a 
therapeutically effective dose in the eye, bioavailability is less than 2% and can require 
high dosage concentrations which can cause toxicity (Morrison and Khutoryanskiy, 
2014). 
 
1.4.3- Intravitreal administration 
Intravitreal injection of drugs into the eye involves direct injection of the formulation, in 
the form of solution, particles, suspension, depot or implants, into the posterior segment 
(Kuppermann and Loewenstein, 2010). Direct drug administration into the vitreous offers 
distinct advantage of more straightforward access to the vitreous and retina, providing 
increased drug concentrations at the neural retina and minimizing systemic side effects 
(Urtti, 2006; Kuppermann and Loewenstein, 2010) 
 
1.4.4- Periocular delivery  
The periocular route includes subconjunctival, subtenon, retrobulbar and peribulbar 
administration and is comparatively less invasive than intravitreal route, being considered 
the least painful and the most efficient route of drug delivery to the posterior eye 
(Gaudana et al., 2010; Kuppermann and Loewenstein, 2010). Drug solutions are placed 
in close proximity to the sclera which results in high retinal and vitreal concentrations as 
the periocular route enables the deposition of molecules against the external surface of 
the sclera because it is made up of fibrous tissue, which offers less resistance to 
permeability of drugs (Gaudana et al., 2010; Kuppermann and Loewenstein, 2010). 
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1.5- Strategies to improve ophthalmic drug delivery 
 
In a general way, for the treatment of ocular pathologies, there are used the conventional 
pharmaceutical forms presented as solutions, suspensions, ointments and gels (table 2). 
However, with the use of these ones only about 5% of the dose reaches the target. So, to 
get a therapeutic effect it is necessary to give repeated or high doses. This both situations 
can cause an increase of interactions or exacerbation of local and/or systemic side effects 
with potent drugs such as timolol (a beta-blocker) (Lallemand et al , 2013). 
 
Table 1.2 - Advantages and disadvantages of conventional ocular drug delivery systems 
(Adapted from Patel et al, 2015) 
 Advantages Disadvantages 
 
 
 
Solution 
 
 
Easy and practical administration 
Elimination by tears and 
nasolacrimal drainage 
Pre-corneal elimination 
Low bioavailability 
Low pharmacological action 
Repeated administrations 
 
Suspension 
Prolonged contact with ocular mucosa 
Useful for low solubility drugs 
Irritation due to particle size 
 
Gel 
Less blurred vision when compared with 
ointments 
Incorporates a great variety of drugs 
 
Adherence to the eyelid 
 
 
Ointment 
Long contact time with ocular mucosa 
No drainage by tears 
Better stability and bioavailability 
Blurred vision 
Adherence to the eyelid 
 
In view of the problems of conventional drug delivery systems, it was necessary to 
develop new pharmaceutical systems that allow the drug to get the tissue in effective 
concentrations. New pharmaceutical systems have to release the drug in an optimized 
way in the local of action. Consequently, there is a need for new formulations that will 
improve efficacy while also limiting the risk of local side effects (Mudgil et al, 2012) 
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1.6- Mucoadhesion and characterization of mucoadhesive properties 
 
One of the main aims currently in topical ocular drug and biopharmaceutical delivery is 
to increase the residence time of the drug at the ocular surface, to increase drug uptake, 
diffusion and transport. This can be done by changing the characteristics of the delivery 
system, for example: by making a liquid system more viscous, but this creates its own set 
of problems for the patient, including blurred vision, which may jeopardize its success. 
However, if the delivery system could specifically bind to the ocular surface, this could 
increase biopharmaceutical residence and release time, decrease the concentration and 
volume required, and also decrease the frequency of treatment administration. This is the 
aim of ocular mucosal drug and biopharmaceutical delivery, by which the specific 
structural components of the mucin layer of the tear film are exploited to become an 
integral part in ocular delivery, which creates a more effective, efficient, and user friendly 
ocular delivery system (Sheardown and Lorentz, 2014). 
An adhesive, is a material that attaches to another substrate surface and resists separation. 
Adhesion involves the formation of attractive bonds between two substrates that resist 
separation. Bioadhesion is a specific case of adhesion in which at least one of the two 
substrates involves a biological tissue. Furthermore, if the adherent substrate surface is a 
mucosal surface, e.g., a mucosal membrane, bioadhesion is specifically referred to as 
mucoadhesion (Wu et al, 2014). 
Mucoadhesive formulations are capable of providing localized drug release in desirable 
regions like the eyes to enhance their clinical efficacy. The employment of mucoadhesive 
materials in formulations may modify the permeability of mucosal tissue or membranes 
and hence facilitate the adsorption of macromolecules (Singh and Rana, 2012). 
Mucoadhesive controlled-release device can improve the effectiveness of a treatment by 
helping to maintain the drug concentration between the effective and toxic levels, 
inhibiting the dilution of the drug in the body fluids, and allowing targeting and 
localization of a drug at a specific site (Huang et al, 2000). 
Mucoadhesion has shown renewed interest for prolonging the residence time of 
mucoadhesive dosage forms through various mucosal routes in drug delivery 
applications. Mucoadhesive-based topical and local systems have shown enhanced 
bioavailability. Mucoadhesive drug delivery gives rapid absorption and good 
bioavailability due to its considerable surface area and high blood flow (Shaikh et al, 
2011). 
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Mucoadhesive drug delivery systems offer several advantages over other delivery 
systems including increased residence time of drug at the site of application, increased 
permeability of drug into the systemic circulation and enhanced bioavailability of the 
drug. 
In general, the mucoadhesion phenomenon can be described in three steps: the first step 
involves wetting and swelling of the polymer to allow an intimate contact with the tissue, 
second, interpenetration and/or entanglement of the polymer and the mucin chains, and 
finally, the formation of weak chemical bonds leading to adhesion of the polymer to the 
mucosal surface. The interactions between a polymer and the mucous layer could be 
physical or mechanical bonds, secondary chemical bonds and covalent chemical bonds. 
Physical bonding implies the entanglement of mucin glycoproteins with the polymer 
chains, and the interpenetration of the mucin chains into the polymer matrix. Secondary 
chemical interactions include polar, van der Waals and hydrogen bonding. Covalent 
bonding could take place between the polymer and the mucosal substrate (Singh and 
Rana, 2012). 
 
1.6.1- Mucoadhesion theories of polymer attachment 
Mucoadhesion is a complex process and has not yet been fully understood and numerous 
theories have been developed to explain the phenomenon of mucoadhesion. No individual 
theory has been universally accepted as the singular mechanism by which bioadhesion 
occurs (Huang et al, 2000) though a combination of theories may be used to describe the 
phenomenon: electronic theory, wetting theory, adsorption theory, and diffusion theory. 
 
1.6.1.1- Electronic theory 
In the electronic transfer theory, mucoadhesion occurs as the result of the transfer of 
electrons between glycoprotein mucin network and the mucoadhesive polymer (Morrison 
and Khutoryanskiy, 2014). This electron transfer occurs because of the difference in 
structure between the bioadhesive and the glycoprotein chains in the mucus. Bioadhesion 
in this case is due to an attraction across the electrical double layer (Wu et al, 2014). 
 
1.6.1.2- Wetting theory 
The ability of mucoadhesive polymer to spread and develop intimate contact with the 
mucus layer is determinant for bond formation. It is best applied to liquid or low-viscosity 
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bioadhesives. It explains adhesion as an embedding process, whereby adhesive agents 
penetrate into surface irregularities of the substrate and ultimately harden, producing 
many adhesive anchors. Free movement of the adhesive on the surface of the substrate 
means that it must overcome any surface tension effects present at the interface (Shaikh 
et al, 2011). Adhesive forces between a liquid and solid enable a liquid drop to spread 
across the surface, whereas, cohesive forces within the liquid cause the drop to ball up 
and avoid contact with the surface. Generally, contact angles less than 90◦ indicate that 
the wetting of the surface is favourable, and the liquid tends to spread out to a large area. 
A contact angle greater than 90◦ indicates the wetting of the surface is unfavourable; the 
interaction among liquid molecules maintains the shape of the droplet and minimizes its 
contact area to the solid surface (Wu et al, 2014). The contact angle may be 
experimentally measured from which interfacial tension (γ) may be derived using the 
Young equation: 
 
γSG = γSL + γLG cos θ 
 
 
 
 
 
 
 
Figure 1.3- Contact angle measurement between a droplet and solid surface. (Reference: 
Wu et al, 2014) 
 
Where γSG is the interfacial tension between solid and gas; γSL is the interfacial tension 
between solid and liquid; γLG is the interfacial tension between liquid and gas; and θ is 
the contact angle between solid and liquid interface. The interfacial tension associated 
with contact angle θ exhibits the degree of wetting. 
When the contact angle θ is 0◦, wetting is complete, the liquid having fully spread across 
the surface of the substrate. In contrast, a contact angle of 180◦ is indicative of no 
wettability.  
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1.6.1.3- Adsorption theory 
The adsorption theory suggests that mucoadhesion is due to primary (ionic and covalent 
bonds) and secondary bond formation. The secondary (weaker) bonds such as Van der 
Waals forces, hydrogen bonding, electrostatic attraction, and hydrophobic interactions 
are the more desirable, resulting in semipermanent interactions that is an important 
criterion for drug delivery systems (Shaikh et al, 2011). 
 
1.6.1.4- Diffusion theory 
Diffusion theory describes that polymeric chains from the bioadhesive interpenetrate into 
glycoprotein mucin chains and reach a sufficient depth within the opposite matrix to allow 
formation of a semipermanent bond (Shaikh et al, 2011). The first step in this process 
involves the creation of an initial contact between the bioadhesive polymer chains and 
the mucus chains. In this step, weak physical forces, e.g., attraction and electronic force, 
dominate the mobility of the polymer chains. The second step involves the 
interpenetration of polymer chains from the delivery system into mucus layer to achieve 
mucoadhesion via more substantial bond formation. For significant interpenetration to 
occur, diffusion of the polymer chains of the dosage form into the mucin layer (and vice 
versa) must occur. Furthermore, the two components should have similar chemical 
structure to obtain the strongest mucoadhesive interaction (Wu et al, 2014). 
 
1.6.2- Factors Affecting Mucoadhesion 
Mucoadhesion may be affected by a number of factors, including hydrophilicity, 
molecular weight, cross-linking, swelling, pH value, and the concentration of the active 
polymer. 
 
1.6.2.1- Hydrophilicity 
Bioadhesive polymers possess numerous hydrophilic functional groups, such as hydroxyl 
and carboxyl. These groups allow hydrogen bonding with the substrate, swelling in 
aqueous media, thereby allowing maximal exposure of potential anchor sites. In addition, 
swollen polymers have the maximum distance between their chains leading to increased 
chain flexibility and efficient penetration of the substrate (Singh and Rana, 2012). 
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1.6.2.2- Molecular Weight 
The interpenetration of polymer molecules is favoured by low-molecular-weight 
polymers, whereas entanglements are favoured at higher molecular weights. The 
optimum molecular weight for the maximum mucoadhesion depends on the type of 
polymer, with bioadhesive forces increasing with the molecular weight of the polymer up 
to 100,000(Shaikh, R et al, 2011). 
 
1.6.2.3- Cross-linking and Swelling 
Cross-link density is inversely proportional to the degree of swelling. The lower the cross-
link density, the higher the flexibility and hydration rate, the larger the surface area of the 
polymer, the better the mucoadhesion. To achieve a high degree of swelling, a lightly 
cross-linked polymer is favoured. However, if too much moisture is present and the 
degree of swelling is too great, a slippy mucilage results and this can be easily removed 
from the substrate (Shaikh et al, 2011). 
 
1.6.2.4- pH value 
The pH value at the bioadhesive to substrate interface can influence the adhesion of 
bioadhesives possessing ionizable groups. Many bioadhesives used in drug delivery are 
polyanions possessing carboxylic acid functionalities. If the local pH value is above the 
pK of the polymer, it will be largely ionized; if the pH is below the pK of the polymer, it 
will be largely unionized. The approximate pK for the poly (acrylic acid) family of 
polymers is between 4 and 5. The maximum adhesive strength of these polymers is 
observed around pH 4–5 and decreases gradually above a pH of 6. A systematic 
investigation of the mechanisms of mucoadhesion clearly showed that the protonated 
carboxyl groups, rather than the ionized carboxyl groups, react with mucin molecules, 
presumably by the simultaneous formation of numerous hydrogen bond. (Park and 
Robinson, 1985) 
 
1.6.2.5- Concentration of Active Polymer 
In highly concentrated systems, beyond the optimum concentration the adhesive strength 
drops significantly. In concentrated solutions, the coiled molecules become solvent-poor 
and the chains available for interpenetration are not numerous. This result seems to be of 
interest only for more or less liquid mucoadhesive formulations. 
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Controlled drug delivery systems aim to deliver drugs at predetermined rates and 
predefined periods of time, targeting drugs to a desirable group of cells. In this 
perspective, nanoscale systems can maximize the efficacy of therapeutic treatments 
(Singh and Rana, 2012). 
 
1.7- Options to overcome physiological barriers 
 
Ocular drug absorption from the lacrimal fluid to the anterior ocular tissues via 
transcorneal absorption is determined by two major factors: drug permeability through 
the cornea and contact time of the product with ocular tissues. Based on these two 
principles, several approaches have been done to overcome the barriers. 
One of the best strategies for improving the bioavailability of ocular drugs is to develop 
delivery systems that act as drug reservoirs, prolonging the residence time, controlling 
the release and, therefore, decreasing the frequency of administration (Almeida et al, 
2014). 
Colloidal carriers present several advantages for ophthalmic administration, like, small 
particle size, adhesive properties, improvement of the bioavailability of poorly water 
soluble drugs, protection of sensitive drug molecules (against enzyme inactivation), 
biodegradable, biocompatible and non-irritant features with corneal epithelial cells, 
improvement of drug pre-ocular retention, promoting absorption, targeted and controlled 
release characteristics, reducing or preventing side effects, being ideal for long-term 
treatments. (Mun et al, 2014). 
Lipid and polymeric nanoparticles are the most promising for ophthalmic drug delivery 
and their use could revolutionize the therapy of many eye diseases. Nanoparticle systems 
are those containing particles with sizes smaller than 1000 nm,The smaller particles are 
better tolerated by patients than larger ones because they are better able to penetrate across 
the corneal barrier, where they will act as reservoir to release the drug slowly to the 
surrounding tissues (Ali and Al-Halafi, 2014). 
 
1.7.1- Polymeric Nanoparticles 
Biodegradable polymeric nanoparticle system, are the most popular systems in ocular 
carrier therapy. These systems can be composed of various polymers in which the drug is 
dissolved, entrapped or encapsulated. Drugs can either be integrated in the matrix or 
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attached to the surface. These systems offer several advantages for ophthalmic drug 
delivery, like biodegradability, non-toxicity, biocompatibility, mucoadhesiveness 
(bioadhesion and interaction with the glycoproteins of the cornea and conjunctiva), ease 
and low cost of production, and the possibility of obtaining stable systems after 
lyophilization and reconstitution, which increases the long-term stability of the systems 
(Almeida et al, 2014). 
Polymers are classified as anionic, cationic and non-ionic (Singh and Rana, 2012). 
Cationic polymers have electrostatic interaction with the negatively charged epithelium 
present on mucosal surface. Mucoadhesion of cationic polymers, such as chitosan occurs 
due to the interactions of their hydroxyl and amino groups with the sialic groups of mucin 
in the mucus layer. Additionally, the linearity of chitosan molecules also ensures 
sufficient chain flexibility for interpenetration (Singh and Rana, 2012). 
Chitosan, a (1–4)-2-amino 2-deoxy β-D-glucan, is a deacetylated form of chitin, which is 
the second-most abundant polymer in nature after cellulose (Vyas et al,2012). 
 
 
 
 
Figure 1.4-Schematic chemical structure of chitosan (Reference: Kunjachan et al, 2010) 
 
Chitosan has one primary amino group and two free hydroxyl groups for each C6 building 
unit. Due to the availability of free amino groups, it carries a positive charge and reacts 
with many negatively charged surfaces such as the cell membrane, mucus lining (due to 
negatively charged sialic acid residues), and also with other anionic polymers (Kunjachan 
et al, 2010 and Rossi et al 2000). 
It is considered a good candidate for ocular drug delivery because it is in the category of 
mucoadhesive polymers that are frequently used as an approach to prolong drug residence 
times. When using a mucoadhesive material, the clearance of the drug is controlled by 
the mucus turnover rate (approximately 15h to 20h), which is slower than the tear turnover 
rate. This prolonged retention of the drug formulation implies, for a drug with good 
permeability properties, an enhanced ocular drug bioavailability (Alonso and Sanchez, 
2003). The mucoadhesive properties of chitosan in the eye are determined by the 
formation of either secondary chemical bonds such as hydrogen bonds or ionic 
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interactions between the positively charged amino groups of chitosan and the negatively 
charged sialic acid residues of mucins, depending on environmental pH (Ludwig, 2005). 
An alternative way to modulate the viscosity and viscoelastic behaviour of chitosan 
solutions could be through the incorporation of other hydrophilic polymers that are known 
to interact with chitosan like hyaluronic acid (Alonso and Sanchez, 2003). 
Chitosan has penetration-enhancing properties, which are attributed to the modulation of 
the tight junction barrier between epithelial cells and also related to intracellular routes. 
Dodane et al, 1998 developed studies using Caco-2 cells and found that chitosan increases 
cell permeability by affecting both paracellular and intracellular pathways of epithelial 
cells in a reversible manner, without affecting cell viability or causing membrane wounds. 
This permeability-enhancing property has been used to explain the increased corneal 
transport of specific drugs. It is a biodegradable polymer, which enables the safe 
administration and degradation of topically applied ocular chitosan vehicles and its 
biodegradation is mediated by the hydrolytic actions of lysozyme and other enzymes (de 
la Fuente et al, 2010). 
For ocular administration it is important to demonstrate that all the excipients used have 
low toxicity and to demonstrate this fact Felt et al. (1999), reported that chitosan has an 
excellent ocular tolerance. These results are based in the data observed in a rabbit model 
following topical instillation of chitosan solutions and using confocal laser scanning 
ophthalmoscopy combined with corneal fluorescein staining (Felt et al, 1999). 
These studies provided evidence of the low irritation caused by chitosan after repeated 
topical administration to the corneal surface of rabbits (4 instillations a day for a period 
of 3 days). Similarly, an acute ocular tolerance test was also performed for chitosan coated 
poly-Ɛ-caprolactone (PCL) nanoparticles (Calvo et al, 1997). The results after repeated 
administration of these systems (2 instillations per hour for a period of 6 h), shown that 
no irritation or appreciable disruptions in the epithelial cells was observed. 
In sum, chitosan is a good polymer to use due to its characteristics: easy of preparation, 
low cost, hypoallergenicity, non-toxicicity, biodegradability, do not interact with drugs. 
Considering the chitosan advantages, a new type of nanosystem composed by chitosan as 
the main component was developed by Calvo et al 1997. Because of its cationic 
composition, chitosan is able to gel when in contact with specific multivalent polianions, 
such as sodium tripolyphosphate (TPP). Chitosan is a weak base, insoluble in water and 
organic solvents but it is soluble in dilute aqueous acidic solution (pH < 6.5), by 
converting the glucosamine units into a soluble form of protonated amine (R–NH3+). 
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Chitosan gets precipitated in alkaline solutions or with polyanions and forms a gel at a 
lower pH (Kunjachan et al, 2010). 
Nanoparticles are spontaneously formed upon mixing of chitosan and TPP solutions, 
through the formation of inter and intramolecular linkages between the phosphate groups 
of TPP and the amino groups of chitosan. The method used is ionotropic gelation and it 
has been possible to incorporate efficiently hydrophilic compounds such as small 
molecules, peptides, proteins and genes through the establishment of electrostatic 
interactions either with the positively charged polymer chitosan or with the negative 
polyanion. The TPP is the main mechanism that governs the entrapment of these active 
compounds. The electrostatic interaction is particularly suited for the incorporation of 
biopharmaceuticals for two reasons: first, the formation process is solely based on the 
electrostatic interaction of oppositely charged polymers; hence, no chemical modification 
needs to be applied; secondly, the incorporation can be achieved in aqueous, 
physiological conditions (Agnihotri et al, 2004). 
 
Besides natural polymers, synthetic mucoadhesive polymers like cellulose derivatives 
(e.g. cellulose-ethers: carboxymethyl cellulose (CMC) and hydroxypropylmethyl 
cellulose (HPMC) were also proposed as viscosifying agents. Cellulose-ethers have 
excellent biocompatibility profiles, stabilize the tear film and increase the contact time 
due to their film forming properties (Ludwig, 2005). 
HPMC is a natural biodegradable and biocompatible anionic polymer obtained from 
natural cellulose by chemical modification, which empirical formula is C8H15O8-
(C10H18O6)n-C8H15O8 and molecular weight is about 86000 ((Huichao et al, 2014). HPMC 
is selected for several formulations as a hydrophilic matrix system because it gives fast 
gel formation to control initial drug release and that the formation of its strong viscous 
gel controls further release. Its popularity can be attributed to its nontoxic nature, ease of 
compression, capability to accommodate a high level of drug loading, good viscosity 
stability between pH 3 and 11 during long-term storage (Huichao et al, 2014). 
Hyaluronic acid (HA) is also incorporated in nanoparticles into the nanoparticles to 
improve their cellular targeting capacity. Although its characteristics of biocompatibility, 
biodegradability, and mucoadhesive character, HA is known for its implication in 
processes, as the regeneration of corneal and conjunctival epithelial cells, through its 
interaction with the CD44 receptor. CD44 is expressed in the human cornea and 
conjunctiva and participates in a wide variety of cellular functions, including receptor-
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mediated internalization and degradation of hyaluronan (de la Fuente et al, 2008). It is 
because of this interaction with CD44 receptors that this system of nanoparticles is 
developed to penetrate the corneal and conjunctival epithelia (de la Fuente et al, 2010). 
 
1.8- Bacterial keratitis 
 
A wide diversity of eye diseases affects millions of people around the world and has 
devastating effects on individuals, leading to visual injury and possible ocular blindness 
that instigate a decline in quality of life (Karsten et al, 2012). 
Bacterial keratitis is an infectious disease of the cornea that is characterised by 
inflammation, often with stromal infiltration by leukocytes, and is considered an 
ophthalmic emergency requiring immediate attention. Keratitis can progress rapidly with 
corneal destruction through pathological wound healing within 24-48 h (Karsten et al, 
2012) that can result in severe visual loss and represents one of the most common causes 
of corneal blindness. 
The common pathogens associated with the disease include Staphylococcus aureus, 
coagulase-negative Staphylococcus, Pseudomonas aeruginosa, Streptococcus 
pneumonia, and Serratia species, causing 90% of the bacterial keratitis cases (Karsten et 
al, 2012). 
The most common keratitis risk factors are the use of contact lenses, corneal trauma, or 
underlying ocular surface disease. 
The use of contact lenses has been closely associated with an increased incidence of 
bacterial keratitis. The introduction of soft contact lenses and their widespread use since 
the 1980s, is closely associated with an increased incidence of bacterial keratitis and 
knowing that 125 million worldwide them it is an important disease to control. Contact 
lenses can serve as a platform for the microbial proliferation, encouraging microbial 
adhesion to the cornea and can also interfere with the ocular defences, by leading to 
hypoxia and/or disruption of the epithelial-tear film interactions allowing the adhesion 
and invasion by the pathogen (Wong et al, 2012). 
Direct corneal damage disrupts the innate immune system of the eye, enabling entry by 
microbes into the abrasion and consequent infection. Corneal surgery is a risk factor for 
microbial keratitis as the corneal epithelial barrier is breached. Due to the immune 
privileged nature of the eye, any break in the corneal epithelium renders the eye 
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susceptible to infection. Furthermore, post-operative care usually requires the use of 
topical steroids to control the immune response. The prophylactic use of corticosteroids 
has become quite controversial and has been associated with an increase in microbial 
growth and keratitis (Karsten et al, 2012). 
 
1.9- Ceftazidime 
 
Therapeutic failures to treat Pseudomonas aeruginosa and Staphylococcus aureus 
infections of the eye with conventional regimens, as well as the emergence of resistant 
strains of these bacteria, have led to the use of fortified antibiotic eye drops in subjects 
who do not respond to conventional treatment modalities, as is often the case in long term 
care (Karampatakis et al, 2009). 
Ceftazidime is a third-generation cephalosporin that acts by inhibition of bacterial cell 
wall synthesis. Ceftazidime has activity in the presence of some beta-lactamases, both 
penicillinases and cephalosporinases, of Gram-negative and Gram positive bacteria. 
According to European Medicines Agency, ceftazidime has been shown to be active 
against most isolates of Gram-negative bacteria (Citrobacter species, Enterobacter 
species, Esscherichia coli, Klebsiella species, Haemophilus influenza, Neisseria 
meningitidis, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia 
species) and Gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumonia, 
Streptococcus pyogenes, Streptococcus agalactiae). 
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2. Materials and Methods 
 
2.1- Materials 
 
Carboxymethyl cellulose (CMC) high and low viscosity, hydroxypropylmethyl cellulose 
(HPMC) low and high viscosity, phosphate buffer saline (PBS buffer), Chitosan low 
molecular weight (LMW), mucin from porcine stomach were obtained  from Sigma–
Aldrich (Dorset, UK). 
Sodium tripolyphosphate (TPP) was obtained from Applichem (Germany). Hyaluronic 
acid (HA) (HA50, HA300 and HA3000 kDa) were kindly provided by Soliance (France) 
and ceftazidime (CFT) from Combino Pharm Portugal. 
Tryptic soy broth (BK046HA) and Tryptic soy agar (15g/L agar-agar) were obtained from 
Biokar (France). Pseudomonas aeruginosa (ATCC® 9027), HEK293T (ATCC® CRL-
11268™) and ARPE-19 (ATCC® CRL-2302™) cell lines were obtained from American 
Type Cell Culture collection (USA). 
Cell culture media and supplements were from Gibco (ThermoFisher Scientific, UK).  
Purified water was of Milli-RX quality (Merck Millipore, Germany). All other reagents 
and solvents were of the purest grade available, and used without further treatment. 
 
2.2- Methods 
 
2.2.1-Preparation of different polymeric solutions 
The polymers used were carboxymethyl cellulose (CMC) of low and high viscosity and 
hydroxypropylmethyl cellulose (HPMC) of low and high viscosity at the percentages of 
0.5%, 1% and 2% (w/V). The polymer powder was weighted according to the percentage 
desired and 20 mL of PBS was added to each sample and left to swell overnight. 
The gel preparation was made in duplicate to evaluate the effect of autoclaving in the 
properties like pH value, viscosity and osmolality. The duplicated solutions were 
sterilized in the autoclave at 121ºC for 15 min. 
 
2.2.1.1- Determination of viscosity 
The viscosity measurements were carried out using a Brookfield viscometer model DVII 
(Brookfield, USA), using the spindle S8. The developed formulations were poured in the 
sampler tube using spindle nº S8. 10 mL of the gel sample was poured in the small sample 
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holder and viscosity measurements were taken at room temperature, every 30 s, at 
different shear rates (SR) in the range 0.5-100 rpm, and the spindle was lowered 
perpendicularly into it. For each sample, duplicate measurements were made, one at 
increasing SR and the other at decreasing SR, to account for time-dependent behavior. 
 
2.2.1.2- pH value determination 
For each gel formulation, the pH value was measured using a pH WTW meter (WTW 
GmbH, Germany) at room temperature. Equipment was previously calibrated using 
standard buffers of pH 4 and pH 7.  
 
2.2.1.3- Osmolality determination 
The osmolality of solutions was measured by the use of an Osmometer K-7400 (Knawer, 
Berlin, Germany). The equipment was previously calibrated at 0 and 300 mOsm/kg.  
 
2.2.2-Preparation of the Nanoparticles 
2.2.2.1- Formulation of CS/TPP/HA nanoparticles 
The nanoparticles were produced by the ionotropic gelation method process based on the 
complexation between oppositely charged macromolecules. At this particular case, the 
positive charge of the hydrophilic polymer is complexed with a multivalent polyanion 
(sodium tripolyphosphate - TPP) to form highly viscous gel particles within the nanosize 
range. The basic mechanism involved in the formation of the nanoparticles is the 
electrostatic interactions between positively charged amino groups present in chitosan 
and negatively charged anion carboxyl and phosphate of HA and TPP previously 
described by Cadete et al. 2012. 
At first, different amounts of CS (1 and 2.5 mg/mL) and TPP (2 and 3 mg/mL) at different 
pH were prepared. CS solutions were prepared by dissolving the polymer in purified 
water with 1% (V/V) acetic acid solution and leaving it under stirring for 3 h. The pH 
value was adjusted to 4, 5 and 6 with a 0.1N sodium hydroxide solution. TPP solutions 
were prepared by dissolving TPP in purified water, and the pH was adjusted to 7.5, 8 and 
9.  
For the production of nanoparticles the proportion of the three components CS, HA and 
TPP, the pH value and the molecular weight of HA had to be optimized. HA was used at 
three different molecular mass, 50, 300 and 3 kDa at the concentration of 10 mg/mL. The 
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assembling of CS an TPP in different concentrations and pH values allows the analysis 
of many formulations with different proportions TPP:CS, from 33:1 to 4:1.   
The HA, at different molecular mass, was added to TPP solution and suffered successive 
dilutions. This mixture was then added to CS solution. The yield of the different 
formulations was measured by optical density (OD) by measuring the samples absorbance 
at a wavelength of 600 nm (FLUOstar Omega, BMG Labtech, Germany).  
 
2.2.2.2- Particle size distribution 
Mean particle size and polydispersity index (PDI) of nanoparticles were assessed by light 
scattering using a Zetasizer Nano-S (Malvern Instruments, UK) at a temperature of 25ºC. 
Nanoparticles were dispersed in 0.22 μm filtered purified water and their distribution size 
was obtained from the average of three different batches.  
 
2.2.2.3-Surface charge evaluation  
The surface charge of the nanoparticles was evaluated through zeta-potential 
measurement at Malvern Zetasizer Nano-Z (Malvern Instruments, UK). Zeta-potential is 
based on dynamic light scattering methodologies while applying an electrical field that 
will polarize an electrophoretic cell and the surface charges will be evaluated due to 
electrophoretic mobility/velocity in the cell through the correlation equation of 
Smoluchowski which relates the velocity of the molecule through the electrical field with 
its charge (Domingues et al., 2009).  
Standard electrophoretic cell was used with gold electrodes to apply the electric field. 
Samples were diluted in 3 mL of 0.22 μm filtered purified water and the cell was filled 
verifying for the existence of bubbles that could cause interference in the zeta-potential 
measurements. All experiments were done in triplicate. 
 
2.2.2.4- Scale up of selected nanoparticles formulation 
The formulation with better characteristics of OD, size and zeta-potential was chosen to 
be scaled-up for 1 mL and 10 mL and formulated as empty nanoparticles and 
nanoparticles loaded with ceftazidime.  
The volumes of the solutions used to prepare a solution of NP with 1 mL and 10 mL are 
presented in table 2.1. The 1mL NP solutions were prepared to be used for the 
encapsulation efficiency test. To evaluate if the method of production of the NP solutions 
can be scaled up, the 1mL NP solution was scaled up 10 times. 
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150 µL of the mix solution of TPP-HA-(CFT) was added to 1 mL of the CS solution and 
the homogenization was performed by pipetting several times. An opalescent suspension 
was immediately obtained. For the solution of 10 mL, the preparation was similar but the 
addition of TPP-HA-(CFT) to chitosan solution was made under constant stirring (300 
rpm). 
After choosing the best nanoparticles formulation, the different concentrations of 
ceftazidime were tested (50, 100, 150 and 200 µg/mL). All the formulations were tested 
in triplicate. 
 
Table 2.1- Composition of nanoparticles solutions 
 
 
2.2.2.5- Nanoparticles production yield 
Chitosan concentration was determined using an indirect method based on the 
quantification of the chitosan concentration initially used in the formulation, and that 
found in the supernatant of the final nanoparticle suspension. The method for chitosan 
quantification was based on a colorimetric reaction between the amine groups of chitosan 
and the dye Cibacron brilliant red 3B-A, adapted to a 96-well microplate (Cadete et al., 
2012). Briefly, 1 mL of the nanoparticles suspension was centrifuged (Sigma 112, 
Solutions Volume (µL) Volume (mL) 
Empty 
NPs 
NPs loaded with CFT Empty NPs NPs loaded with 
CFT 
CS  
(1 mg/mL) 
1000 1000 10 10 
TPP 
(3mg/mL) 
75 75 0.75 0.75 
HA 50 
(10mg/mL) 
19 19 0.19 0.19 
CFT 
(10mg/mL) 
- 5 10 15 20 - 0.2 
H2O 56 115 110 105 100 0.56 0.36 
Total: 1.150ml Total: 11.50 ml 
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Germany) at 12000×g for 15 min at room temperature in order to separate the 
nanoparticles from free chitosan. 
After the addition of the dye to the solutions the absorbance values were measured at 575 
nm in FLUOstar Omega (BMG Labtech, Germany). Standard curve was created using a 
known range of chitosan concentrations in the same conditions as the unknown samples. 
Unknown chitosan concentration in each sample was determined using linear regression 
analysis. Thus, it was possible to determine the chitosan yield (CS yield) using the 
following equation: 
  
 
CS yieldሺ%ሻ =
ሾCSሿtotal − ሾCSሿsupernatant
ሾܥܵሿݐ݋ݐ݈ܽ
×100 
[CS]total is the concentration of chitosan used to prepare the nanoparticles and [CS] 
supernatant is the concentration of chitosan in the supernatant. 
 
2.2.2.6-Quantification of Ceftazidime 
The quantification was assessed by UV-Visible spectrophotometry, at λmax of 256 nm, 
in a microplate spectrophotometer reader (FLUOstar Omega, BMGLabtech, Germany). 
Calibration curves with standard concentrations in the range of 250-1.95 µg/mL were 
used. 
 
2.2.2.7- Encapsulation efficiency 
Encapsulation efficiency (EE) was determined by quantification of CFT in the 
supernatants (i.e., non-encapsulated CFT) obtained during nanoparticles preparation. 
Antibiotic detection was performed as previously described (2.2.2.6.) The EE is 
expressed as the percentage of antibiotic encapsulated in particles reported to the initial 
amount of antibiotic used for particle preparation. The encapsulation efficiency (EE) of 
the ceftazidime was determined by subtracting the free drug amount from the initial added 
amount of the drug. The (EE %) was calculated by the following equation: 
 
EE (%) =ሾ୧୬୧ୡ୧ୟ୪ େ୊୘ሿିሾୱ୳୮ୣ୰୬ୟ୲ୟ୬୲ େ୊୘ሿሾ୧୬୧୲୧ୟ୪ େ୊୘ሿ  ×100 
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2.2.3- Bioadhesion studies 
The bioadhesion was evaluated by viscosity and zeta potential measurements. 
The viscosities of the polymeric solutions were determined at room temperature by using 
the Ostwald viscometer, by means of the following equation: 
 
ƞ1 =  ƞ2. ρ1t1/ρ2t2 
Where ƞ1 and ƞ2 are viscosity coefficients of our solution and water, ρ1 and ρ2 are the 
densities of the solution and water, and t1 and t2 are the flow times measured in the 
viscometer of the solution and water, respectively.   
The viscosities of HPMC 0.5% high viscosity, mucin and nanoparticles were measured. 
At first, the viscosity of each individual component was determined and after that, to 
evaluate the effect of mucin interaction in the solutions two sets of samples were 
prepared: 1) mucin was added to the solutions of HPMC 0.5%, empty NP and empty NP 
gel; 2) the same study was developed with ceftazidime nanoparticles.   
The viscosity component due to bioadhesion or rheological synergism parameter was 
obtained with the equation (Hassan and Gallo, 1990): 
 
ηt = ηm + ηp ηb 
Where ηt is the viscosity coefficient of the system, and ηm and ηp are the individual 
viscosity coefficients of mucin and bioadhesive polymer, respectively. ηb is the viscosity 
component due to bioadhesion. 
Another method to evaluate the nanoparticles-mucin interaction was determined by 
measuring the zeta potential of the mixtures of mucin and particles system using a 
Zetasizer Nanoseries Nano Z (Malvern Instruments, Malvern, UK).  
 
2.2.4- In vitro ceftazidime release studies 
The ceftazidime release from nanoparticles involved an in vitro assay using pre-
assembled dialysis device membrane (Float-A-Lyzer G2, pore size cut-off of 100 kDa, 
Spectrum Labs, Germany).  
The samples analysed were: empty nanoparticles, empty nanoparticles with HPMC, 
ceftazidime nanoparticles and ceftazidime nanoparticles with HPMC. Suspensions with 
empty nanoparticles were used as control. Five samples of the suspensions of ceftazidime 
nanoparticles were analysed.  
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To each membrane 1 mL of nanoparticles suspension was added and 15 mL of the 
receptor phase composed by phosphate-buffered saline (PBS) pH 7.4. The system was 
kept in agitation (300 rpm) in a shaker (Labinco LD-40, Netherlands) at 37ºC during 24h. 
At pre-determined intervals (0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6 h) (200 µL of the receptor 
phase was collected to a 96 well-plate). The withdrawn aliquots were always replaced 
with equal volume of PBS pH 7.4, maintained at the same temperature.  The released 
ceftazidime was quantified by the technique previously described (2.2.2.6). 
In order to investigate the mechanism of ceftazidime release from the nanoparticles and 
the gel, the release data were fitted to different kinetic models including: zero-order, first-
order, Higuchi, and Korsmeyer–Peppas (Costa and Lobo, 2001). 
 
 
2.2.5- In vitro ceftazidime permeation studies 
Franz cells are largely used for in vitro permeation studies because of the simplicity in 
the use. The diffusion cells used were a system of two compartments, donor and receptor, 
separate by a membrane (Karn, 2014) 
The receptor compartment has an approximate volume of 5 mL and a diffusion area of 1 
cm2. The membranes used in the diffusion assay were Tuffryn® synthetic membranes 
made of hydrophilic polysulfone, with 0.45 μm of porosity. The samples were then 
applied (0.192 g ± 0.1 g) on the surface of the membrane in the donor compartment and 
immediately sealed with Parafilm® to prevent evaporation. 
The receptor compartments were filled with approximately 5mL of PBS buffer pH 7.4, with 
all air bubbles expelled from the compartment. The weight of each one was determined. 
Aliquots (200 µL) of the samples were added to the donor compartment and the weight was 
also measured. All the systems were maintained at the temperature of 37ºC with constant 
stirring (300 rpm) using a magnetic bar. 
The permeation study was carried out for 6 h. During the first hour the samples were collected 
at each fifteen minutes and after that time at each hour. At each determined time, 200 µL of 
the receptor phase was collected to a 96 well-plate. The withdrawn aliquots were always 
replaced with equal volume of PBS pH 7.4, maintained at the same temperature. All 
experiments were carried out using 5 cells per formulation and performed under sink 
conditions during the whole experiment. Samples were analysed for ceftazidime content 
by the previously described technique (2.2.2.6). 
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2.2.6- Microbiological assay 
2.2.6.1- Agar diffusion method 
Tryptic soy agar was used as the growth medium, with a concentration of 15g/L 
agar-agar, this solution was sterilized in an autoclave at 121ºC for 15 min. Under aseptic 
conditions, the Tryptic soy agar containing the microorganism Pseudomonas aeruginosa 
(ATCC 9027) was placed in a Petri dish and solidified. Paper discs were positioned on 
the solid agar. The samples of free CFT, empty CS/TPP/HA NP, and empty NP in HPMC 
gel and CS/TPP/HA NP in gel were placed in the paper discs in triplicate. The volumes 
used were 15, 7.5 and 5 µL, three paper discs for each sample were considered. To 
evaluate a possible loss in the antimicrobial activity with time, samples of CS/TPP/HA 
NP with 1 day and with 2 months were also placed in the paper discs in triplicate. The 
Petri dishes were incubated at 35 ± 2°C overnight. In this assay the parameter used to 
study the antimicrobial activity was the mean diameter of the inhibition zone formed 
around the disc, after incubation. The diameters were measured using a Vernier caliper.  
 
2.2.6.2- Microtitre plate antibacterial assay 
This microtitre plate antibacterial assay was adapted from the method previously 
described according to the guidelines of Clinical and Laboratory Standards Institute 
(CLSI), 2012 by broth microdilution method. To perform this assay the medium used was 
Tryptic soy broth (TSB) (BK046, Biokar, France) which allows the growth of a large 
number of species including the more fastidious like P. aeruginosa. The dehydrated 
medium was reconstituted with purified water to obtain a final concentration of 30g/L, 
after stirring until complete dissolution the tubes containing the medium were sterilized 
in an autoclave at 121ºC for 15 min. Under aseptic techniques a colony of microorganism 
P. aeruginosa was transferred into a bottle containing the TSB medium, the bottle was 
capped and incubated overnight at 35 ± 2°C. The optical density of P. aeruginosa was 
recorded at 600 nm, and various dilutions were made with aseptic techniques until the 
optical density was between 0.5-1.0. The dilution was carried out to achieve a 
concentration of 1×106 cfu/mL. To evaluate the possible differences in the antimicrobial 
effect of CS/TPP/HA NP prepared in different times, we used in this assay NP with 1 day 
and 2 months, in addition the antimicrobial effect of NP in gel and of free CFT was 
evaluated. The final concentration of free CFT and CFT in NP used in this assay was 
100µg/mL.  
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The plate was prepared under aseptic conditions; a sterile 96 well plate was used. The NP 
samples and free CFT were subject to serial dilutions. Finally, the 50µL of 1×106 cfu/mL 
bacterial suspension was added to each well to achieve a concentration of 5×105 cfu/mL. 
The plate was incubated at 35±2°C overnight. The turbidity change was first assessed 
visually. A vital dye, resazurin (Alamar Blue), was added to all wells in the plate and 
incubated for 3h. To confirm the positive and negative results the wells fluorescence 
intensity was measured in a microplate spectrophotometer reader (FLUOstar Omega, 
BMGLabtech, Germany). The first concentration with no sign of bacterial growth 
(sample with low fluorescence intensity) was taken as the MIC (minimum inhibitory 
concentration) value.  
 
2.2.7- In vitro cell assays 
2.2.7.1- Cell viability 
The cytotoxicity was assessed using general cell viability endpoint resazurin 
reduction (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) (Alamar Blue) assay (Ferreira et 
al, 2015, Nociari et al, 1998)and propidium iodide (PI) dye exclusion assays (Mehanna 
et al, 2011). The resazurin is a blue dye, weakly fluorescent that is reduced by viable cells 
into the pink colored and highly red fluorescent resorufin. The propidium iodide (PI) is a 
red fluorescent probe that is a cell membrane impermeant and, therefore, only penetrates 
membrane integrity compromised cells. When PI does gain access to nucleic acids, and 
intercalates them, its fluorescence increases dramatically and it is, therefore, used to 
identify membrane integrity compromised cells.  
Cell viability was assessed after 24h of incubation with different concentrations 
of the formulations. The day before experiment HEK293T (human embryonic kidney cell 
line, ATCC® CRL-11268™) and ARPE-19 (human retinal pigment epithelial cell line, 
ATCC® CRL-2302™) cell lines were seeded in sterile flat bottom 96 well tissue culture 
plates (Greiner, Germany), in RPMI 1640 culture medium (Life Technologies, UK), 
supplemented with 10% Fetal serum bovine (Life Technologies, UK), 100 units/mL of 
penicillin G (sodium salt) (Life Technologies, UK), 100 μg/mL of streptomycin sulfate 
(Life Technologies, UK), 2mM L-glutamine (Life Technologies, UK), at a cell density of 
2×105 cells/mL. Cells were incubated at 37ºC and 5% CO2. 
On the next day, medium was replaced by fresh medium containing the different samples 
to be analyzed. Each concentration was tested in six wells per plate. Cells were incubated 
for 48h, negative control was the culture medium and positive control sodium dodecyl 
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sulfate (SDS) at 0.1 mg/mL. After the time of exposition, the medium was replaced by 
0.3 mM propidium iodide in culture medium (stock solution 1.5 mM in DMSO, diluted 
with culture medium 1:5000). Fluorescence was measured (excitation, 485 nm; emission, 
590 nm) in microplate reader (FLUOstar Omega, BMGLabtech, Germany), and then, the 
Alamar Blue assay was performed. Medium was replace by medium containing 5 mM of 
resazurin. The cells were further incubated for 3h and the fluorescence at 530 nm of 
excitation wavelength and 590 nm of emission wavelength was measured in a 
fluorescence microplate reader (FLUOstar Omega, BMGLabtech, Germany). 
The relative cell viability (%) compared to control cells was calculated by 
[Fluorescence]sample/[Fluorescence]control×100 for the Alamar Blue assay and 
[Fluorescence]sample/[Fluorescence]control for PI uptake assay. 
 
2.2.7.2- Oxidative stress assay 
The intracellular reactive oxygen species (ROS) production was determined using 
the 2-7’dichlorodihydrofluorescein diacetate (H2-DCFDA) dye. DCFH-DA is a stable, 
non-fluorescent molecule that is hydrolyzed by intracellular esterases to non-fluorescent 
2-7’-dichlorodihydrofluorescein (DCFH), which is rapidly oxidized in the presence of 
oxygen radicals to a highly fluorescent compound (DCF) (Crow, 1997). Cultures at same 
cell density for cell viability assay (2.2.7.1) of ARPE-19 and HEK 293T cells grown in 
96-well plates were incubated, after exposed for 24h at different samples, 30 min with 20 
μM of H2-DCFDA (Life Technologies, UK) in the dark at 37ºC. The medium was then 
removed and fresh medium was added. Hydrogen peroxide solution (Applichem, 
Germany) was used as a positive control for the induction of ROS in cells and media 
alone as a negative control. ROS levels were determined at excitation 485 nm and 
emission 520 nm wavelengths using a florescence microplate reader (FLUOstar 
BMGLabtech, Germany). Data from 6 replicates are reported as relative fluorescence 
units (RFU) percentage and expressed as mean fluorescence ratio (fluorescence of 
exposed cells/fluorescence of unexposed control from the same experiment) (Crow, 
1997).   
 
2.2.8- Statistical Data Analysis 
The data was expressed as mean and standard deviation (mean ± SD) of 
experiments. Statistical evaluation of data was performed using one-way analysis of 
variance (ANOVA). Tukey–Kramer multiple comparison test (GraphPad PRISM 5 
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software, USA), was used to compare the significance of the difference between the 
groups, a P <0.05 was accepted as significant. 
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3. Results and Discussion 
 
3.1 Preparation of the Nanoparticles 
 
The nanoparticles were produced by the ionotropic gelation method process based on the 
complexation between oppositely charged macromolecules.  
At first, different amounts of CS (1 and 2.5 mg/mL) and pH values of 4, 5 and 6 and TPP 
(2 and 3 mg/mL) at different pH values 7, 8 and 9 were tested. 
For the production of the nanoparticles it has to be optimized the proportion of the three 
components CS, HA and TPP, the pH value and the molecular weight of HA. HA was 
used at three different molecular mass, 50, 300 and 3000 kDa at the concentration of 10 
mg/mL. The assembling of CS and TPP in different concentrations and pH allows the 
analysis of many formulations with different weight proportions CS:TPP:, from 33:1 to 
4:1.  The yield of the different formulations was measured by optical density (OD) 
measuring the samples absorbance at a wavelength of 600 nm. 
With the solution of CS 2.5mg/mL and for the two tested concentrations of TPP solution 
and pH values containing 5mg/mL of HA 50kDa values present aggregates (table 3.1). 
 
Table 3.1. Screening of the preparation of the nanoparticles for different concentrations 
of TPP at fixed concentration of HA 50kDa of 5mg/mL and two concentrations of CS and 
three pH values. 
 CS 2.5 mg/mL CS 1 mg/mL 
 pH 4 pH 5 pH 6 pH 4 pH 5 pH 6 
TPP 2 mg/mL pH 7 +AH 
50kDa  
A A A NT T T 
TPP 2 mg/mL pH 8+AH 50kDa A A A NT T T 
TPP 2 mg/mL pH 9+AH 50kDa A A A NT T T 
TPP 3 mg/mL pH 7+AH 50kDa A A A NT T T 
TPP 3 mg/mL pH 8+AH 50kDa A A A NT T T 
TPP 3 mg/mL pH 9+AH 50kDa A A A NT T T 
A-aggregates; NT-not turbid; T-turbid (Ratio volume of TPP/HA to CS was 1:7) 
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Thus further studies were performed with CS at 1mg/mL for the pH values of 5 and 6 
(table 3.2). 
 
Table 3.2. Screening of the preparation of the nanoparticles for two concentrations and at 
two pH values of TPP with different concentrations of HA 50kDa, 300kDa and 3000kDa 
with 1 mg/mL CS and two pH values. 
 CS 1 mg/mL 
 pH 5 pH 6 
TPP 2 mg/mL pH 8+AH 50kDa T T 
TPP 2 mg/mL pH 9+AH 50kDa T T 
TPP 3 mg/mL pH 8+AH 50kDa T T* 
TPP 3 mg/mL pH 9+AH 50kDa T* T* 
TPP 2 mg/mL pH 8+AH 300kDa A A 
TPP 2 mg/mL pH 9+AH 300kDa A A 
TPP 3 mg/mL pH 8+AH 300kDa A A 
TPP 3 mg/mL pH 9+AH 300kDa A A 
TPP 2 mg/mL pH 8+AH 3000kDa A A 
TPP 2 mg/mL pH 9+AH 3000kDa A A 
TPP 3 mg/mL pH 8+AH 3000kDa A A 
TPP 3 mg/mL pH 9+AH 3000kDa A A 
A-aggregates; T-turbid; T*- Particles size >2000nm 
(Ratio volume of TPP/HA to CS was 1:7) 
 
The concentration of HA was changed on the range of 10mg/mL to 0.04mg/mL and it 
was possible to observed that for high molecular mass 300kDa and 3000kDa or the 
particles aggregates or the size was higher than 1000nm, in all the tested conditions.  
The chosen formulation to proceed was the one with a considerable yield of production 
and size range lower than 1000 µm (table 3.3). 
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Table 3.3- Composition of the selected nanoparticles (size, polydispersity index (PdI) 
and Zeta potential (mean±SD, n=3) 
 Volume 
(µL) 
Size (nm)/PdI Zeta Potential 
(mV) 
CS (1mg/mL, pH 5) 1000 795±14 
 
0.363±0.073 
 
+40±1 TPP (3mg/mL. pH 
7.0)  
75 
HA 50 (10 mg/mL) 19 
H2O 56 
  
 
3.2 Selection of adequate polymer to contain CS/HA nanoparticles 
The main purpose of the developed work was the development of an effective ceftazidime 
carrier system to be used to deliver the antibiotic directly into the eye. It is an innovation 
way to apply ceftazidime because nowadays this antibiotic is only used for intravenous 
treatments. 
CS/HA nanoparticles were selected for ocular delivery, due to chemical and biological 
properties of hyaluronic acid and chitosan, such as biocompatibility, biodegradability, 
mucoadhesiveness and non-toxicity, as described previously (Kunjachan et al, 2010). 
Nanoparticles are carrier systems that must allow improving the efficacy of drug delivery 
by overcoming diffusion barriers, permitting reduce doses as well as sustained delivery 
and appear to be the most promising tool to meet the primary requirements of and ideal 
ocular delivery system (Almeida et al, 2014). 
The most important aspect in the development of eye drops is the compatibility with the 
ocular mucosa. All ocular formulations must ensure isotonicity (osmolality close to 300 
mOsm/kg), pH similar to the physiological fluids (pH 7.4), optimal viscosity and sterility 
(Almeida et al, 2014) 
To produce nanoparticles ocular instillation, two different polymers to incorporate the 
nanoparticles were studied: HPMC and CMC high and low viscosity. The two polymers 
were tested in three different concentrations 0.5, 1 and 2% (w/v).  Because ophthalmic 
preparations have to be sterile the first test was to verify if the polymer maintained the 
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same characteristics before and after sterilization by autoclave (121ºC for 15 minutes). 
The determination of gels viscosity is important because it must have the correct viscosity 
that allows to increase the ocular contact time increasing de mucoadhesiveness and with 
this increase bioavailability.  It cannot be so fluid that have a rapid drainage and not so 
viscous that cause blurred vision (Zambito and Colo, 2011) 
Both HPMC and CMC 0.5, 1 and 2% (w/v) have a Newtonian behavior and the viscosity 
of the gels, autoclaved and not autoclaved, is very similar when comparing the same 
polymer solution with equal concentration (data not shown).This means that autoclaving 
does not interfere with the rheology of the gel. By analyzing the viscosity values (table 
3.4) obtained for all the tested polymers the ones that were selected to proceed with other 
tests were: HPMC 1%(w/v)  low viscosity, HPMC 0.5%(w/v)  high viscosity, CMC l% 
(w/v) low viscosity and CMC 0.5% (w/v).     
 
Table 3.4- Determination of the gel viscosity 
Solution (w/v) Viscosity Autoclaved gel 
(mPa.s) 
Viscosity non autoclaved 
gel (mPa.s) 
 
HPMC 
54.5 57 
174 170 
210 300 
 
CMC 
85 100 
88,5 95 
Non-Newtonian fluid 
 
3.3 Determination of pH value and Osmolality 
 
The selected polymer concentrations were evaluated according to their pH and 
Osmolality to ensure that they are compatible with the ocular mucosa. The European 
Pharmacopoeia 8th, the monograph “Ophthalmic Preparations” indicates that the value of 
pH 7.4 and osmolality around 300 mOsm/kg correspond to an isotonic solution. 
The results obtained (table 3.5) show that autoclaving does not affect pH and osmolality 
values, being an advantage because sterilization does not interfere with the desired 
characteristics for the final formulation. The evaluated polymers can ensure isotonic 
formulations allowing that any of them can be used in the final formulation of the eye 
drops. 
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Table 3.5 - Determination of pH value and Osmolality 
Solution (w/v) 
pH value Osmolality  (mOsm/ Kg) 
Autoclaved 
gel 
Non 
autoclaved 
gel 
Autoclaved 
gel 
Non 
autoclaved 
gel 
HPMC LV 1%  7.34 7.34 260 270 
HPMC HV 0.5%  7.36 7.35 254 271 
CMC LV 1% 7.35 7.35 266 267 
CMC HV 0,5% 7.35 7.30 261 268 
 
3.4 Determination of Zeta Potential 
Results in table 3.6 show that autoclaving does not affect significantly ZP values, being 
once again the advantage to achieve a sterile formulation without affecting its properties.  
 
Table 3.6 - Zeta potential (ZP) values of the tested polymeric solutions 
(mean±SD, n=3) 
Solution (w/v) 
ZP (mV) 
Autoclaved 
gel 
Non 
autoclaved 
gel 
HPMC LV 1%  -2±0 -11±2 
HPMC HV 0.5%  -3±2 -9±5 
CMC LV 1% -26±103 -31±4 
CMC HV 0.5% -24±5 -31±3 
 
The ZP values demonstrate that CMC and HPMC solutions have negative values but with 
significant differences between them. A possible explanation for this difference could be 
that HPMC has a nonionic nature while CMC is anionic, which makes its surface charge 
more negative (Sosnik et al,2014). The distribution of the ZP values is shown on figures 
3.1 and 3.2. 
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Figure 3.1 - Distribution of ZP in CMC 
 
 
Figure 3.2 - Distribution of ZP in HPMC 
 
After the characterization of the polymers (pH, osmolality and ZP), it is concluded that 
both could be used to prepare two different eye drop formulations to increase CFT 
absorption and bioavailability. However, after combining CS/TPP/HA it was observed 
that with CMC the nanoparticles precipitated instead of what happened with HPMC that 
maintained nanoparticles stable in solution (Figure 3.3). CMC has a negative charge and 
for this reason it interacts with the positive charges of CS/TPP/HA nanoparticles resulting 
in flocculation of the nanoparticles. In contact with mucin, it has been described that the 
interaction of CMC with mucin is good only at low pH value. When the pH increases the 
adhesive interactions are practically absent; a possible explanation could be the fact that 
the pKa of CMC is near 3.5, which means that above this value the polymer is negatively 
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charged leading to the establishment of repulsive forces with the negative charges from 
the mucin chains (Sosnik et al, 2014). 
In its turn HPMC has a charge near zero and for this reason it allows nanoparticles to be 
maintained in suspension. For this reason, HPMC was the selected polymer to contain the 
CFT nanoparticles. In fact, HPMC is largely used in pharmaceutical formulations as 
lubricant for the treatment of the Dry Eye Syndrome (Zambito and Colo, 2011). 
 
 
 
 
 
 
 
Figure 3.3– Incorporation of ceftazidime nanoparticles in CMC 0.5% and 1% 
(w/V) polymer (A) and HPMC 0.5% and 1% (w/V)  (B)  
 
3.5 Nanoparticles encapsulating CFT 
 
Because CFT suffers degradation in aqueous solutions, it was necessary to develop a 
different system to make the topical ocular administration. NP was the developed system 
to interact with the mucosal barrier with the objective of favoring the transport of 
macromolecules into the ocular mucosa. Developed polymeric NP represent an approach 
as they can entrap macromolecules and protect them against degradation and are able to 
increase ocular penetration and bioavailability due to their small particle size (Bravo-
Osuna, 2016).  The use of mucoadhesive polymers allows the interaction with the mucus 
layer increasing the biopharmaceutical residence and release time. Natural bioadhesive 
polysaccharides like HA and CS are particularly interesting for the development of 
polymeric NP intended for ophthalmic administration. The association of these two 
polymers is intended to promote the utility of the nanocarriers for the ocular delivery of 
macromolecules (Singh and Rana, 2012).  
A B 
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The mechanism of formation of these NP is believed to combine the hydrogen bonds and 
electrostatic interaction between CS and HA (that are oppositely charged) with the ability 
of CS to gel spontaneously due to its ionic interaction with polyanion TPP. The addition 
of the TPP crosslinker is responsible for the formation of very organized structures, due 
to the reticulation of the nanosystems, TPP is a non-toxic molecule which can form a gel 
by ionic interactions between the positively charged amino groups of CS and the 
multivalent anions of TPP (de la Fuente et al, 2008). Because ceftazidime has a polar 
character (logP= -1.6), its encapsulation in CS/TPP/HA NP is probably achieved through 
hydrogen bonds and electrostatic interactions (Wijesooriya, 2013). 
The developed CFT nanoparticles maintained the same characteristics of the empty NPs 
as shown in table 3.7 
 
Table 3.7 – Determination of NP´s size, polydispersity index (PdI) and Zeta potential 
(mean±SD, n=3) 
 
CFT 
(µg/mL) 
Size (nm) PdI  ZP (mV) 
Empty NP 0 795±14 0.363±0.073 +40±1 
 
CFT NP 
50 632±11 0.280±0.010 +37±1 
100 743±7 0.360±0.070 +38±0 
150 675±11 0.290±0.040 +39±0 
200 654±4 0.300±0.050 +37±1 
 
The obtained NP has the required characteristics: high and positive zeta potential to 
provide electrostatic stabilization, the dimensions in the range of 100-1000nm and narrow 
size dispersity.  
The obtained size of CFT NP is adequate to ocular administration in eye drops and it is 
easily transported across biological barriers.  
The polydispersity index (PDI) smaller than 0.4 indicates a relative homogeneous 
dispersion. The positive ZP values indicate that the surface of the NP is mostly composed 
by CS. The positive charge of the particles is desirable to prevent particle aggregation and 
promote electrostatic interaction with the negatively charged sialic acid residues of mucin 
in the eye surface (Singh and Rana, 2012). The ZP value higher than ±30mV indicates a 
nanosuspension stable by electrostatic repulsion which leads to a more uniform size 
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distribution. The stability of the particles is important to prevent their aggregation 
(Gonçalves et al, 2010). 
The scale-up of NP formulation ten times, to a final volume of 10mL, was 
accomplished and can be verified that their characteristics are similar to the NP 1mL 
samples. This information is important to prepare a CFT eye drop formulation that could 
be commercially manufactured for the treatment of eye infections. The main factor 
affecting the CFT association to the NP is probably electrostatic interactions. CFT is in a 
HA/TPP solution with a basic pH, consequently its charge is mostly negative which 
enhances CFT interactions with the free amino groups present in the CS acidic solution 
(de la Fuente et al, 2008). 
Wijesooriya et al. (2013), developed a liposomal formulation containing CFT, 
when using a cationic lipid DOTMA to encapsulate CFT.  In the study it was observed a 
decrease in the EE. The explanation for this result was the electrostatic interactions 
between the lipid bilayer and the drug that negatively influenced the rate of encapsulation 
due to their positive charges. This explanation seems reasonable as our results confirm 
that when CFT is added directly to the CS solution with pH=5, where CS has also a 
cationic nature, the EE is lower than when CFT is added to mix solution. The positively 
charged quaternary ammonium of CFT may play a significant role in the aforementioned 
fact. Thus, the addition of CFT to the solution of TPP/HA/H2O mix, that has a higher pH 
value, allow CFT to be negatively charged which promotes the interaction with CS 
enabling a more efficient CFT encapsulation in the NP. However, we managed to have 
higher encapsulation efficiencies with CS/TPP/HA NP than with liposomes. This may 
have occurred because the LMW chitosan is a small molecule (MW: 50000-190000 Da) 
comparing to the cationic lipid DOTMA (MW: 670575 Da), so it is possible that in 
liposomes the effect of electrostatic interactions have a stronger effect in the 
encapsulation of CFT. 
The Encapsulation Efficiency (table 3.8) determined as indicated in section 2.2.2.7, shows 
a high percentage of encapsulated CFT, allowing to conclude that the developed process 
is highly effective for the maximum tested concentration. 
 
 
 
 
 
42 
 
Table 3.8- Determination of ceftazidime Encapsulation efficiency (EE) (mean±SD, 
n=12) 
 
 
 
 
3.6 In vitro ceftazidime release studies 
 
For the NP in solution, 50% of the dug was released after 3h, while for the NP included 
in the HPMC, at the same time, 30% of CFT was released (figure 3.4.). These values 
remained stable over 24h (data not shown).  The drug release from the NP seemed to have 
two different stages, an initial fast release of ≈25% for the NP+HPMC gel and ≈40% in 
the NP in solution until the first hour (figure 3.4).  This was followed by a slower 
exponential release of the remaining drug over the next hours. The initial rapid release, 
known as “burst effect”, occurs due to the fact that some of CFT were adsorbed on the 
surface of NP which could be released easily by diffusion, additionally there are amounts 
of CFT that were not encapsulated and remained on solution and so they have a fast 
dissolution in the release medium.  After the initial burst effect, a slower sustained release 
occurs which can be attributed to the slow diffusion of the encapsulated drug out of the 
polymeric matrix of NP into the release medium. These release profiles support the idea 
that some CFT molecules were encapsulated among the positively charged hydrophilic 
chains of CS and the remaining molecules were either adsorbed to the NP surface or free 
in solution. The HPMC gel is another possible barrier to the drug release, with lower 
values for drug dissolution in the release medium. The gel entraps the CFT molecules to 
achieve a prolonged drug release, suggesting that the diffusion rate of CFT from the NP 
can me modified by increasing the viscosity of solution. 
 
 
 
 
EE (%) 
NP CFT 
(200µg/mL) 
 
78.4± 1.0 
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Figure 3.4 - Release profiles of CFT from CS/HA/TPP nanoparticles in 10 mM PBS pH 
7.4 at 37 ºC  (mean ± SD, n = 3). 
 
CFT release values were fit to different mathematical models (zero-order, first-order, 
Higuchi and Kormeyer-Peppas). The release data for NP and NP+HPMC best fitted to 
the Korsmeyer-Peppas model (table 3.9) This model of drug release is used when more 
than one type of mechanism of drug release is involved. Moreover, the Korsmeyer-Peppas 
release model exponent, n, is less than 0.5 for both formulations which suggests that the 
Fickian diffusion is the controlling factor in drug release. (Dash et al, 2010) The release 
rate of CFT through the vehicle network to the external medium is significantly dependent 
on the rate of molecular diffusion of CS/TPP/HA nanoparticulate system. 
 
Table 3.9- Mathematical models and respective parameters (correlation coefficients and 
kinetic constants) obtained from fitting the CFT release experimental data. 
 Zero-order First-order Higuchi Korsmeyer–Peppas 
 
r2 
k0 
(µg/h) 
 
r2 
k1 
(h-1) 
 
r2 
kH 
(h-0.5) 
 
r2 
kKP  
(hn) 
n 
NP 0.87 6.22 0,89 0.14 0,87 12,44 0,98 0,60 0.27 
NP Gel 0.86 6.13 0,89 0.11 0,86 12,25 0,91 0,59 0.28 
r2: correlation coefficient; k0: zero-order release constant; k1: first-order release constant; kH: Higuchi 
constant kKP: Korsmeyer–Peppas constant; n: release mechanism exponent.  
 
 
 Gel 
 Nanoparticles 
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3.7 In vitro ceftazidime permeation studies 
 
Permeation studies were developed for NP in solution and incorporated in HPMC using 
Franz cells with cellulose membranes.  
There is a very similar profile between the permeation of CFT through the membranes 
when administered in NP solution and NP+HPMC. The amount of CFT released from NP 
in solution is slightly higher than from NP in HPMC. In this case the maximum release 
of CFT is 20% . 
CFT permeation from NP in HPMC is smaller than NP in solution and it is expected 
because gel formulation has a higher viscosity resulting in a more compact polymer 
matrix that reduces the degradation of the polymer and/or the diffusion of the loaded CFT 
from the NP. As observed before in the release studies, the permeation profiles also show 
an initial burst phase due to the absorbed CFT in the surface of NP that is followed by a 
slow permeation of the trapped drug (figure 3.5). 
 
 
 
 
 
 
 
 
 
Figure 3.5 – Permeation profile of NP solution and NP gel in 10mM PBS pH 7.4 
through a cellulose membrane at 37ºC (mean ± SD, n=6) 
 
 
 
 
 Nanoparticles 
 Gel 
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3.8 Mucoadhesive studies 
 
The interaction and stability of CS/TPP/HA NP in solution and incorporated in HPMC 
gel in the presence of mucin was determined by measuring the viscosity of a mucin 
dispersion before and after incubating with the NP. This determination is essential 
because the blink process requires a low tear viscosity to avoid damaging the corneal 
epithelium so it is ideal that the viscosity of the NP solution does not increase significantly 
when interacting with mucins. Mucins are elongated molecules composed of a chain 
containing an amide group that confer its hydrophobic characteristics and branching 
chains of sugar enriched with serine, threonine and proline, with hydroxyl, carboxylic and 
sulfate groups that result in highly hydrophilic nature. Furthermore, mucin contains at the 
end of its molecule an amino terminus and a carboxyl terminus (Sheardown and Lorentz, 
2014). 
It was studied the effect of interaction of NP in solution and in HPMC with mucin in the 
viscosity of the system, because a higher interaction with mucin is related with higher 
viscosity.  
The results of the study with an Ostwald viscometer presented in figure 3.6. show an 
increase of viscosity for CFT NP when compared with empty NP. This difference is more 
evident in the presence of HPMC allowing to understand that CFT plays an important 
role in the increasing of viscosity.  
The developed system with CFT NP and HPMC, in the presence of mucin, shows an 
increase of viscosity, allowing to concluded that mucoadhesion is ensured. This 
interaction between NP and mucin is due to the fact that the carboxylic acid groups of 
mucin are ionized at the pH value of 6 and therefore they are freely accessible for 
interaction with the positively charged amine groups of CS (present in the NP). 
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Figure 3.6 - Viscosity determination for NP and HPMC in presence and absence of 
mucin 2% (w/V) 
 
 ZP results of the nanoparticles incubated with mucin dispersion suggest that interactions 
between mucin and NP are present. The ZP profiles obtained for tested solutions with 
mucin and with water support this observation; the ZP values are reduced for the solutions 
containing mucin. These results are consistent with the ones obtained by De Campos et 
al (2004) in experiments with CS and mucin. This reduction can be attributed to the ionic 
interactions between the negatively charged mucin particles and the positive charges of 
CS/TPP/HA NP, resulting these interactions in a reduced surface charge and ZP value 
(table 3.10). 
 
Table 3.10 - Determination of zeta potential for NP and NP in HPMC for 
different concentration of mucin (mean ± SD, n=3) 
Mucin 
Conc. Mucin NP Gel+NP 
(mg/mL) ZP (mv) ZP (mv) ZP (mv) 
0   +34±1 +2±0 
5 -24±1 -5±1 -5±1 
10 -21±1 -15±1 -8±0 
20 -18±0 -14±1 -12±2 
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3.9 Microbiological assay 
 
3.9.1 Agar diffusion method 
The agar diffusion method intended to test the susceptibility of P. aeruginosa to CFT. It 
was used free CFT in solution, encapsulated CFT in NP and encapsulated CFT in NP 
within HPMC gel. In this method it is the diameter of the inhibition zone that allows to 
verify the efficacy of the antibiotic against the pathogen, because the diameter of the 
inhibition zones are proportional to the sensitivity of the microorganism (Bonev et al, 
2008). 
As expected, and as a control, there is no inhibition zone (0mm) for empty NP (table 
3.11). The obtained results suggest a difference in the antimicrobial activity of CFT in the 
NP formulation and in NP+HPMC gel formulation. The inhibition zone of NP+HPMC 
gel formulation was smaller than the ones we obtained for the NP solutions. It can be 
explained as the fact that HPMC gel acts as a barrier for drug diffusion out of the 
polymeric matrix and this results in a decreased concentration of antibiotic near the 
bacterial cells and lowest antimicrobial effects. The solution of free CFT obtained the 
higher inhibition zone however this value is not very distant from those resulting from 
the NP formulations. 
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Table 3.11 – Antimicrobial activity of NP solutions, NP gel and free CFT against bacterial 
test organism (P. aeruginosa) - inhibition zones in mm 
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3.9.2- Microtitre plate antibacterial assay 
This microtitre plate antibacterial assay was adapted from the method previously 
described by Sarker et al. (2007) and according to the guidelines of Clinical and 
Laboratory Standards Institute (CLSI) by broth microdilution method. To evaluate the 
possible differences in the antimicrobial effect of CS/TPP/HA NP prepared in different 
times, NPs with 1 day and 1 month were teste. In addition, the antimicrobial effect of NP 
in gel and of free CFT was tested. The final concentration of free CFT and CFT in NP 
used in this assay was 100µg/mL. The results are shown on the table 3.12.  
 
Table 3.12 – Antimicrobial activity of NP solutions, NP gel and free CFT against bacterial 
test organism (P. aeruginosa). MIC results in µg/ml. 
Solution MIC (µg/mL) 
NP solution  0.78 
NP solution 1 month 4ºC 1.56 
NP Gel solution  1.56 
NP Gel solution 1 month 4ºC  3.13 
Free CFT 0.78 
 
The results of the microtitre plate antibacterial assay (table 3.12) are in accordance with 
the agar diffusion test. The MIC value of the NP formulation and free CFT solution was 
found to be 0.78µg/mL for the tested P. aeruginosa. Values in conformity with the work 
of Sueke et al 2010. The same inhibitory concentration for these formulations reveal that 
the incorporation of CFT into the matrix of CS/TPP/HA NPs was successful in 
maintaining CFT antimicrobial activity. The MIC value of the NP gel formulation was 
significantly higher (1.56µg/mL) probably for the same reason described in the section 
above. It is noted an increase of the MIC after one month of storage at 4ºC for both NP 
and NP Gel formulations. The increase of the MIC can be related to the degradation of 
the non-encapsulated antibiotic. 
Previous investigations have proposed different mechanisms of antibacterial activity of 
NP. Some studies refer that NP can fuse with the microbial cell wall and then the 
antibiotic is released within the cell wall and membrane (Zhang et al, 2010). Others report 
that NP are able to bind to the cell wall and act as a drug depot releasing the antibiotic 
50 
 
continuously. The released drug diffuses into the inner compartments of the bacteria 
(Zhang, 2010). To determine the exact mechanism in vivo of CS/TPP/HA NP more tests 
will be necessary. 
 
3.10 In vitro cell assays 
 
3.10.1 Cell viability 
The results of cell viability for the different tested samples obtained from the Alamar Blue 
and PI assays are presented in Figure 3.7. These results shown a good profile in terms of 
cell viability of ARPE-19 and HEK 293T cell lines, measured by a metabolic assay and 
membrane integrity assay. The results showed that these formulations were not toxic for 
the cells at concentrations below 200 µg/mL. These results are in agreement with 
previously published data where the tested formulation of NP showed 100% of cell 
viability (de la Fuente et al, 2010).
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Figure 3.7- Cell viability of HEK293T (A;B) and ARPE-19 (C,D) cell lines 
exposed for 24h to 200 µg/mL of formulations (A,C- PI ratio uptake; B,D- 
Rezasurin reduction) (mean ± SD, n=6) 
 
 
3.10.2 Oxidative stress assay 
The ability of NPs to induce intracellular oxidant production in HEK 293T and ARPE-19 
cells was assessed using DCF fluorescence, which reacts with oxygen radicals. All 
samples do not significantly increase the intracellular ROS production after 24h of 
exposition for the two cell lines tested as shown in Figure 3.8. 
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Figure 3.8- Reactive oxygen species (ROS) (Cells exposed 24h to 200µg/mL of 
formulations; A- HEK293T cell line and B-ARPE-19 cell line) (mean ± SD, n=6) 
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4. Conclusion 
 
The main purpose of this research work was the development of an effective CFT 
nanocarrier system that could be used to deliver the antibiotic directly into the eye, in 
order to act as a future therapy against Bacterial Keratitis.  
CFT has been proven to be a powerful antimicrobial agent against a wide range of 
microorganisms responsible for eye infections, like Staphylococcus aureus and 
Pseudomonas aeruginosa.  
CFT- loaded CS/HA formulations were characterized for their physiochemical properties 
revealing distribution sizes between 631.6±11.25 and 742.9±6.58 nm, and zeta potential 
values between 37.2±0.7 and 38.8±0.08 mV, being suitable for ocular applications. CFT 
encapsulation efficiency of CFT was 78.4±0.96% into NP showing a low waste of the 
antibiotic. Positive charge of CS, allows the interaction of NP with hydroxyl and amino 
groups with the sialic groups of mucin in the mucus layer, prolonging the residence time 
in the eye. 
CFT NPs have as a vehicle, HPMC 0.5% HV and this cellulose derivative presented the 
desired characteristics: adequate viscosity that allows prolonged contact time of the drug 
in the ocular globe and does not cause blurred vision; the pH value around 7.4 and the 
osmolality near 300mOsm/kg are similar to the physiological fluids and considered 
adequate. 
The mucoadhesivity studies for the formulations (NPs included in HPMC) allows to 
confirm the increased interaction with the ocular mucin and increased residence time of 
the antibiotic in the eye. 
The results of antimicrobial assays reveal that encapsulating CFT in NP does not change 
its antimicrobial activity which remains sufficient to inhibit bacterial growth. Also, in 
vitro cytotoxicity studies revealed that formulations were not toxic for ARPE-19 and 
HEK 293T cells lines. 
To sum up, developed chitosan coated hyaluronic acid ceftazidime loaded nanoparticles 
seem to be an interesting and potential therapy for bacterial keratitis treatment.  
This work constitutes an important “proof of concept” step and can be completed in the 
future by studying other biological and pharmaceutical properties of the developed 
nanoparticles, including: sustained release testing, evaluation of nanoparticles stability 
when in contact with ocular fluids, namely tear film, and retain the long-term stability of 
developed nanoparticles after freeze-drying and sterilization. 
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